What is FluidForm?
Based in the Boston innovation hub, FluidForm stands as the global leader in functional human tissue development for research, repair, and replacement applications. The company utilizes its patented FRESH 3D printing platform—a technology validated by high-impact scientific literature—to create structurally complex tissue models. By bridging the gap between traditional bioprinting and clinical-grade bioprosthetics, FluidForm addresses critical unmet needs in human health. Their current operational focus spans the development of implantable medical devices and sophisticated tissue models designed to enhance drug efficacy testing and cardiotoxicity screening, positioning the firm at the intersection of biotechnology and advanced manufacturing.
How much funding has FluidForm raised?
FluidForm has raised a total of $310K across 2 funding rounds:
Debt
$150K
Debt
$160K
Debt (2020): $150K with participation from PPP
Debt (2021): $160K led by PPP
Key Investors in FluidForm
PPP
Public-Private Partnership
What's next for FluidForm?
With this late-stage capital injection, FluidForm is strategically positioned to scale its preclinical programs and transition its bioprosthetic pipeline toward clinical validation. The company's roadmap emphasizes the refinement of its biofabrication infrastructure to meet the rigorous demands of organ replacement research. As the firm matures, the focus will likely shift toward expanding its commercial partnerships with pharmaceutical entities seeking more accurate, human-relevant testing models. By leveraging its robust intellectual property portfolio, FluidForm aims to set the industry standard for complex tissue engineering, ultimately moving closer to its long-term objective of providing viable, lab-grown solutions for organ replacement and regenerative medicine.
See full FluidForm company page
